CY1123982T1 - Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ) - Google Patents
Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)Info
- Publication number
- CY1123982T1 CY1123982T1 CY20211100276T CY211100276T CY1123982T1 CY 1123982 T1 CY1123982 T1 CY 1123982T1 CY 20211100276 T CY20211100276 T CY 20211100276T CY 211100276 T CY211100276 T CY 211100276T CY 1123982 T1 CY1123982 T1 CY 1123982T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- multiple myeloma
- administered
- patient
- effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Abstract
Η παρούσα αποκάλυψη σχετίζεται με την θεραπευτική αντιμετώπιση του πολλαπλού μυελώματος. Το μονοκλωνικό αντίσωμα MOR202 είναι αποτελεσματικό όταν χορηγείται σε έναν ασθενή σε συγκεκριμένα σχήματα δοσολογίας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15167597 | 2015-05-13 | ||
PCT/EP2016/060810 WO2016180958A1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123982T1 true CY1123982T1 (el) | 2022-05-27 |
Family
ID=53174925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100276T CY1123982T1 (el) | 2015-05-13 | 2021-03-30 | Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ) |
Country Status (23)
Country | Link |
---|---|
US (2) | US10533057B2 (el) |
EP (1) | EP3294769B1 (el) |
JP (2) | JP7160533B2 (el) |
KR (1) | KR20180008571A (el) |
CN (1) | CN107614530A (el) |
AU (1) | AU2016260895B2 (el) |
CA (1) | CA2984464C (el) |
CY (1) | CY1123982T1 (el) |
DK (1) | DK3294769T3 (el) |
ES (1) | ES2862708T3 (el) |
HR (1) | HRP20210552T1 (el) |
HU (1) | HUE054271T2 (el) |
IL (1) | IL255552B (el) |
LT (1) | LT3294769T (el) |
MX (1) | MX2017014396A (el) |
PL (1) | PL3294769T3 (el) |
PT (1) | PT3294769T (el) |
RS (1) | RS61668B1 (el) |
RU (1) | RU2723047C2 (el) |
SG (1) | SG11201708691VA (el) |
SI (1) | SI3294769T1 (el) |
WO (1) | WO2016180958A1 (el) |
ZA (1) | ZA201708386B (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017014396A (es) * | 2015-05-13 | 2018-03-23 | Morphosys Ag | Tratamiento de mieloma multiple. |
CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
WO2019186273A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
WO2020160020A1 (en) * | 2019-01-28 | 2020-08-06 | Sanofi | Methods of treating multiple myeloma |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗cd38ヒト抗体及びその用途 |
MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
ES2716874T3 (es) * | 2005-03-23 | 2019-06-17 | Genmab As | Anticuerpos contra cd38 para el tratamiento del mieloma múltiple |
EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
EP1945671A2 (en) | 2005-10-12 | 2008-07-23 | MorphoSys AG | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
NZ574978A (en) * | 2006-08-07 | 2012-08-31 | Dana Farber Cancer Inst Inc | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
DK2081595T3 (da) * | 2006-09-26 | 2019-07-15 | Genmab As | Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
RU2595839C2 (ru) | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
WO2014089279A1 (en) * | 2012-12-05 | 2014-06-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds |
CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
SG10201803288RA (en) * | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
CN113134095A (zh) | 2014-06-16 | 2021-07-20 | 梅约医学教育与研究基金会 | 治疗骨髓瘤 |
WO2016022589A2 (en) * | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
EP3191187B1 (en) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
MX2017014396A (es) * | 2015-05-13 | 2018-03-23 | Morphosys Ag | Tratamiento de mieloma multiple. |
-
2016
- 2016-05-13 MX MX2017014396A patent/MX2017014396A/es unknown
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en active Application Filing
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Application Discontinuation
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-04-07 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3294769B1 (en) | 2021-01-13 |
RU2017137496A3 (el) | 2019-06-13 |
US11591406B2 (en) | 2023-02-28 |
CN107614530A (zh) | 2018-01-19 |
EP3294769A1 (en) | 2018-03-21 |
JP2021130668A (ja) | 2021-09-09 |
RU2017137496A (ru) | 2019-06-13 |
IL255552A (en) | 2018-01-31 |
WO2016180958A1 (en) | 2016-11-17 |
CA2984464A1 (en) | 2016-11-17 |
HRP20210552T1 (hr) | 2021-05-14 |
JP2018515513A (ja) | 2018-06-14 |
AU2016260895A1 (en) | 2017-11-09 |
US20200079871A1 (en) | 2020-03-12 |
SG11201708691VA (en) | 2017-11-29 |
PT3294769T (pt) | 2021-04-13 |
US20190048091A1 (en) | 2019-02-14 |
AU2016260895B2 (en) | 2021-08-05 |
PL3294769T3 (pl) | 2021-07-05 |
JP7160533B2 (ja) | 2022-10-25 |
SI3294769T1 (sl) | 2021-07-30 |
RU2723047C2 (ru) | 2020-06-08 |
IL255552B (en) | 2022-01-01 |
RS61668B1 (sr) | 2021-04-29 |
MX2017014396A (es) | 2018-03-23 |
US10533057B2 (en) | 2020-01-14 |
ES2862708T3 (es) | 2021-10-07 |
LT3294769T (lt) | 2021-04-26 |
CA2984464C (en) | 2023-10-10 |
ZA201708386B (en) | 2019-06-26 |
HUE054271T2 (hu) | 2021-08-30 |
KR20180008571A (ko) | 2018-01-24 |
DK3294769T3 (da) | 2021-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123982T1 (el) | Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ) | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
CY1123358T1 (el) | Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη | |
EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
EA201890093A1 (ru) | Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина | |
CY1126036T1 (el) | Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας | |
EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
CY1121436T1 (el) | Δοσολογια για τους αναστολεις των kinασων janus (jak) | |
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
EA201590359A1 (ru) | Лечение ревматоидного артрита | |
EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
CL2021001025A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana |